Gena Wang
Stock Analyst at Barclays
(3.18)
# 1,123
Out of 5,109 analysts
239
Total ratings
44.23%
Success rate
1.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $82 → $87 | $63.29 | +37.46% | 5 | Dec 22, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $34.13 | +46.50% | 7 | Nov 24, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $94 → $90 | $22.85 | +293.87% | 7 | Nov 13, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $7.90 | +317.72% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $32.29 | -22.58% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $9.42 | +48.62% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.43 | +132.56% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $77.71 | -12.50% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $22.00 | -9.09% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $459.21 | -9.85% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $5.90 | +52.54% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $7.53 | +19.52% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $398.70 | +32.18% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $80.33 | +18.26% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $61.14 | +30.85% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $4.88 | +63.93% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $27.45 | -38.07% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $14.35 | +157.84% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $72.14 | -14.06% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $56.46 | -0.81% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $27.77 | -24.38% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.99 | +417.53% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.19 | +36.99% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $26.79 | -66.41% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $6.43 | +288.80% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.87 | +128.72% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.91 | +52.28% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.30 | +5,088.68% | 1 | Jan 6, 2017 |
Cytokinetics
Dec 22, 2025
Maintains: Overweight
Price Target: $82 → $87
Current: $63.29
Upside: +37.46%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $34.13
Upside: +46.50%
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $94 → $90
Current: $22.85
Upside: +293.87%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $7.90
Upside: +317.72%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $32.29
Upside: -22.58%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $9.42
Upside: +48.62%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.43
Upside: +132.56%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $77.71
Upside: -12.50%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $22.00
Upside: -9.09%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $459.21
Upside: -9.85%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $5.90
Upside: +52.54%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.53
Upside: +19.52%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $398.70
Upside: +32.18%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $80.33
Upside: +18.26%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $61.14
Upside: +30.85%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $4.88
Upside: +63.93%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $27.45
Upside: -38.07%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $14.35
Upside: +157.84%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $72.14
Upside: -14.06%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $56.46
Upside: -0.81%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $27.77
Upside: -24.38%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.99
Upside: +417.53%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.19
Upside: +36.99%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $26.79
Upside: -66.41%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $6.43
Upside: +288.80%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.87
Upside: +128.72%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.91
Upside: +52.28%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.30
Upside: +5,088.68%